共 50 条
- [41] Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II studyANNALS OF ONCOLOGY, 2023, 34 : S481 - S482Patel, M. R.Doi, T.Koyama, T.Falchook, G. S.Friedman, C. F.Piha-Paul, S. A.Gutierrez, M.Awad, M. M.Mattour, A. H.Satoh, T.Okamoto, N.Singh, J.Yoshizuka, N.Qian, M.Qian, X.Tran, B. P.Dosunmu, O.Lu, P.Johnson, M. L.
- [42] NBTXR3 ACTIVATED BY RADIOTHERAPY IN COMBINATION WITH NIVOLUMAB OR PEMBROLIZUMAB IN PATIENTS WITH ADVANCED CANCERS: RESULTS FROM AN ONGOING DOSE ESCALATION PHASE I TRIAL (STUDY 1100)JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A714 - A714Shen, ColetteFrakes, JessicaNiu, JiaxinWeiss, JaredCaudell, JimmySeiwert, TanguySaid, PatriciaGuedj, MickaelTyan, PavelVivar, OmarSzyldergemajn, SergioFarber, LeonardRosenberg, Ari
- [43] Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Heinrich, Michael C.von Mehren, MargaretDemetri, George D.Fletcher, Jonathan A.Sun, Jichao G.Kerstein, DavidConlan, Maureen G.George, Suzanne
- [44] Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2024, 35 : S693 - S693Champiat, S.Italiano, A.Wagle, N.Prenen, H.Greillier, L.Bourien, H.Whitman, E.Quinson, A-M.Luecke, S.Hern, V.Lauer, U.
- [45] Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumorsCANCER RESEARCH, 2019, 79 (13)Schram, AlisonSpreafico, AnnaOliva, MarcBrana, IreneGarralda, ElenaLakhani, NehalVon Hoff, DanielBorazanci, ErkutPandya, NaimishHoffman, KimberlyHallett, RobinGiblin, PatriciaAnido, JuditKelly, AdrianneWasserman, RobertSeoane, JoanSiu, LillianHyman, David M.Tabernero, Josep
- [46] Weekly paclitaxel, carboplatin, and bexarotene for the treatment of patients with advanced non-small cell lung cancer: Efficacy results from a phase I/II study.JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 681S - 681SPetty, WJDragnev, KHBlack, WCCole, BFHammond, SWilliams, IDmitrovsky, ERigas, JR
- [47] Phase I/II study of biweekly pemetrexed plus cisplatin in patients with locally advanced, nonresectable or metastatic urothelial cancer: Safety and efficacy results from phase II.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Lopez Martin, AnaBellmunt, JoaquimPablo Maroto, JoseGallardo, EnriqueLopez Brea, MartaLuis Perez-Gracia, JoseCastellano, Daniel E.Maria Valverde, ClaudiaBezares, SusanaCalvo, EmilianoPaz-Ares, Luis
- [48] ST101, a peptide targeting oncogenic transcription factor C/EBPβ: initial safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data from an ongoing phase 1 dose escalation study in patients with advanced, metastatic solid tumorsMOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)Lakhani, Nehal J.Arkenau, Hendrik-TobiasSymeonides, Stefan N.Evans, JeffryMcKean, Meredith A.Fontana, ElisaBupath, ManojkumarMcLaren, AlistairChandana, SreenivasaDing, Tze-enLim, Emerson A.Rotolo, JimCapiaux, GinaMichel, RobKaesshaefer, StephenBexon, Alice S.Falchook, Gerald S.
- [49] First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumorsANNALS OF ONCOLOGY, 2024, 35 : S504 - S504Cheng, X.Song, Z.Yao, J.Yang, J.Wang, M.Zhou, H.Sun, T.Wang, Q.Wu, L.Miao, J.Mi, Y.Lin, J.Zhao, H.Xing, S.Wu, H.
- [50] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumorsEUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34McKean, M.Barve, M.Hong, D.Parikh, A.Rosen, E.Yang, J.Picard, R.Yi, J.Brail, L.Vecchio, D.Meniawy, T.John, T.Wang, J.